Dei, Silvia; Braconi, Laura; Trezza, Alfonso; Menicatti, Marta; Contino, Marialessandra; Coronnello, Marcella; Chiaramonte, Niccolo; Manetti, Dina; Perrone, Maria Grazia; Romanelli, Maria Novella; Udomtanakunchai, Chatchanok; Colabufo, Nicola Antonio; Bartolucci, Gianluca; Spiga, Ottavia; Salerno, Milena; Teodori, Elisabetta published an article about the compound: 8-Bromooctan-1-ol( cas:50816-19-8,SMILESS:OCCCCCCCCBr ).Related Products of 50816-19-8. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:50816-19-8) through the article.
In this study, a new series of N,N-bis(alkanol)amine aryl ester heterodimers was synthesized and studied. The new compounds were designed based on the structures of our previous arylamine ester derivatives endowed with high P-gp-dependent multidrug resistance reversing activity on a multidrug-resistant leukemia cell line. All new compounds were active in the pirarubicin uptake assay on the doxorubicin-resistant erythroleukemia K562 cells (K562/DOX). Compounds bearing a linker made up of 10 methylenes showed unprecedented high reversal activities regardless of the combination of aromatic moieties. Docking results obtained by an in silico study supported the data obtained by the biol. tests and a study devoted to establish the chem. stability in phosphate buffer solution (PBS) and human plasma showed that only a few compounds exhibited a significant degradation in the human plasma matrix. Ten selected non-hydrolysable derivatives were able to inhibit the P-gp-mediated rhodamine-123 efflux on K562/DOX cells, and the evaluation of their apparent permeability and ATP consumption on other cell lines suggested that the compounds can behave as unambiguous or not transported substrates. The activity of these the compounds on the transport proteins breast cancer resistance protein (BCRP) and multidrug resistance associated protein 1 (MRP1) was also analyzed. All tested derivatives displayed a moderate potency on the BCRP overexpressing cells; while only four mols. showed to be effective on MRP1 overexpressing cells, highlighting a clear structural requirement for selectivity. In conclusion, we have identified a new very powerful series of compounds which represent interesting leads for the development of new potent and efficacious P-gp-dependent MDR modulators.
There are many compounds similar to this compound(50816-19-8)Related Products of 50816-19-8. if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.